RxDoctor Payments Data

Bernice Moore

Psychiatric/Mental Health · Whitehall, PANPI 1750809919

Payments from drug & device makers

$1,032in general payments, 2019–2025

Across 47 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$323
  • AbbVie$159
  • Neurocrine Biosciences, Inc.$116
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$68
  • Takeda Pharmaceuticals U.S.A., Inc.$59
  • Alkermes, Inc.$53
  • plus $254 from 7 others

What the payments were for

  • Food & beverage$98595%
  • Education$475%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,032 in reported general payments places this provider in the 65th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$48,018
Medicare patients
120
Services billed
1,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole12$34,423
RexultiBrexpiprazole21$30,577
VraylarCariprazine Hcl19$27,597
Lurasidone Hcl83$20,074
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl105$13,559
TrintellixVortioxetine Hydrobromide24$13,258
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine245$7,021
Adderall XrDextroamphetamine/Amphetamine19$5,587
SavellaMilnacipran Hcl12$5,557
Aripiprazole126$4,970
Chlorpromazine Hcl20$4,681
Bupropion XlBupropion Hcl172$4,294
Quetiapine Fumarate331$3,801
Alprazolam435$3,234
Venlafaxine Hcl ErVenlafaxine Hcl261$2,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$49$65,00033 claims
AbbVieVraylar, Savella$159$33,15431 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$59$13,25824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Whitehall

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →